• Eocene's wholly owned subsidiary Colospan signed its first European distribution agreement with Hospital Line for its CG-100 device.
• Hospital Line secured exclusive rights to market, sell and distribute CG-100 in Greece and Cyprus, subject to mutually agreed commercial targets.
• Colospan plans to launch CG-100 at the 17th Hellenic-Cypriot Surgical Conference, alongside its ongoing US pivotal study.
• The device, designed to reduce the need for diverting stomas, is CE marked but not approved for US commercial use.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EoCene Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO93849) on November 10, 2026, and is solely responsible for the information contained therein.